Time filter

Source Type

Beijing, China

Shi G.,Chinese Institute of Aviation Medicine | Guo X.,Chinese Institute of Aviation Medicine | Xiong D.,Chinese Institute of Aviation Medicine | Wang Y.,Beijing Institute of Technology | And 2 more authors.
Jisuanji Fuzhu Sheji Yu Tuxingxue Xuebao/Journal of Computer-Aided Design and Computer Graphics | Year: 2013

To optimize the design of virtual environment and improve the availability of virtual reality, binocular vision related simulator sickness in post-exposure virtual environment is studied. We first propose a perceived depth formula of parallax stereo display based on the mechanism of binocular visual perception and stereo display of virtual reality. By comparing the differences of human vision perception in the real environment, planar display and virtual environments, we find that the vision discomfortness and the simulator sickness are mainly caused by the fixed user accommodation in virtual environments. This statement is validated by investigating the change of user AC/A of pre- and post-exposure virtual environment and the behavior of the simulator sickness within an simulation flight experiment. We also propose a new scheme for decreasing the risk of the simulator sickness in virtual environment design and simulated training.

Xu J.,PLA Fourth Military Medical University | Li J.,No. 323 Hospital of PLA | Wu X.,PLA Fourth Military Medical University | Song C.,General Hospital of Airforce | And 9 more authors.
Protein Expression and Purification | Year: 2015

In order to obtain bioactive α-bungarotoxin (αBtx) using recombinant protein technique, a codon-optimized synthetic gene was expressed in fusion with the N-terminal 10-His-tag and C-terminal Strep-tag in Escherichia coli. Further optimization through site-directed mutagenesis enabled moderate expression of the protein without the N-terminal His-tag or the C-terminal Strep-tag. Two such recombinant αBtx (rαBtx) were obtained, both with an additional methionine and a glycine at the N-terminal and one with (G4S1)2-Strep-tag at the C-terminal. The rαBtx proteins were refolded using a novel protocol, which efficiently produced final products with activity similar to its natural counterpart. The protocol could easily be scale up, which produced 0.3-1 mg of pure and highly active rαBtx per liter of E. coli culture. © 2015 Elsevier Inc. All rights reserved.

Zheng Y.,Chinese PLA General Hospital | Cai G.-Y.,Chinese Peoples Liberation Army | Chen X.-M.,Chinese PLA General Hospital | Fu P.,University of Sichuan | And 59 more authors.
Chinese Medical Journal | Year: 2013

Background Data on the epidemiology of hypertension in Chinese non-dialysis chronic kidney disease (CKD) patients are limited. The aim of the present study was to investigate the prevalence, awareness, treatment, and control of hypertension in the non-dialysis CKD patients through a nationwide, multicenter study in China. Methods The survey was performed in 61 tertiary hospitals in 31 provinces, municipalities, and autonomous regions in China (except Hong Kong, Macao, and Taiwan). Trained physicians collected demographic and clinical data and measured blood pressure (BP) using a standardized protocol. Hypertension was defned as systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg, and/or use of antihypertensive medications. BP <140/90 mmHg and <130/80 mmHg were used as the 2 thresholds of hypertension control. In multivariate logistic regression with adjustment for sex and age, we analyzed the association between CKD stages and uncontrolled hypertension in non-dialysis CKD patients. Results The analysis included 8927 non-dialysis CKD patients. The prevalence, awareness, and treatment of hypertension in non-dialysis CKD patients were 67.3%, 85.8%, and 81.0%, respectively. Of hypertensive CKD patients, 33.1% and 14.1% had controlled BP to <140/90 mmHg and <130/80 mmHg, respectively. With successive CKD stages, the prevalence of hypertension in non-dialysis CKD patients increased, but the control of hypertension decreased (P<0.001). When the threshold of BP <130/80 mmHg was considered, the risk of uncontrolled hypertension in CKD 2, 3a, 3b, 4, and 5 stages increased 1.3, 1.4, 1.4, 2.5, and 4.0 times compared with CKD 1 stage, respectively (P<0.05). Using the threshold of <140/90 mmHg, the risk of uncontrolled hypertension increased in advanced stages (P<0.05). Conclusions The prevalence of hypertension Chinese non-dialysis CKD patients was high, and the hypertension control was suboptimal. With successive CKD stages, the risk of uncontrolled hypertension increased.

Wang Z.J.,Translational Research Ministry of Education | An T.-T.,Translational Research Ministry of Education | Mok T.,Chinese University of Hong Kong | Yang L.,Translational Research Ministry of Education | And 10 more authors.
Chinese Journal of Cancer Research | Year: 2011

Objective: To analyze the outcomes of patients who received TKI immediately after the first-line without progression as maintenance treatment (immediate group) vs. those received delayed treatment upon disease progression as second-line therapy (delayed group). Methods: The study included 159 no-small-cell lung cancer (NSCLC) patients who received gefitinib or erlotinib as maintenance treatment in the immediate group (85 patients) or as second-line therapy in the delayed group (74 patients). The primary end point was progression-free survival (PFS). EGFR mutation status was detected using denaturing high-performance liquid chromatography (DHPLC). Results: PFS was 17.3 and 16.4 months in the immediate and delayed groups respectively (hazard ratio [HR] 0.99*95% Confidence Interval [CI]: 0.69-1.42*P=0.947). In a subgroup analysis that included only patients with EGFR mutation however PFS was significantly longer in the immediate group than in the delayed group (HR 0.48*95% CI: 0.27-0.85*P=0.012). In patients with wild type EGFR the risk for disease progression was comparable between the two groups (HR 1.23*95% CI: 0.61-2.51*P=0.564). No significant difference was demonstrated between the immediate and delayed group in terms of the overall survival (OS) (26.1 months vs. 21.6 months respectively*HR=0.537z.ast;95% CI: 0.27 to 1.06*P=0.072). There was also no difference in the incidence of adverse events between the two groups. Conclusions: EGFR TKI maintenance improves PFS in patients with EGFR mutation. Prospectively designed clinical studies that compare TKI immediate vs. delayed treatment after first-line chemotherapy upon disease progression are needed. © 2011 Chinese Anti-Cancer Association and Springer-Verlag Berlin Heidelberg.

Discover hidden collaborations